Impact of Trans-Arterial Chemo-Embolization on Tumor Response in Hepatocellular Carcinoma Patients: A Retrospective Study: Tumor Response in Hepatocellular Carcinoma Patients

Abdul Maajid Khokhar; Ayyaz Khan; Zartash  Gull

doi:10.54393/pbmj.v6i09.933

Authors

Abdul Maajid Khokhar Department of Medical Imaging Technology, Riphah International University, Faisalabad, Pakistan
Ayyaz Khan Department of Allied Health Sciences, Government College University, Faisalabad, Pakistan
Zartash Gull Department of Medical Imaging Technology, Riphah International University, Faisalabad, Pakistan

DOI:

https://doi.org/10.54393/pbmj.v6i09.933

Keywords:

TACE, Hepatocellular Carcinoma, m-RECIST Criteria, Tumor Necrosis, Disease Response, CT Triphasic Liver

Abstract

Trans-arterial Chemo-embolization is a treatment done for hepatic metastatic tumors caused by Chronic Liver Disease to reduce the tumor load on the liver. Objective: To assess the treatment response of TACE (Trans-Arterial Chemo-Embolization) in patients with HCC (Hepatocellular Carcinoma) based on the m-RECIST criteria. Methods: The retrospective study was conducted for a duration of one year; from December 2021 to December 2022. The Data were collected from Allied Hospital Faisalabad. TACE was done on a total of 80 patients with Hepatocellular Carcinoma ages between 31 to 80 years and the response was evaluated by m-RECIST criteria on a CT Triphasic scan. The chi-square test was used to find the association between gender and tumor response. Results: A total of 80 TACE-treated patients of Hepatocellular Carcinoma, (n=56) 70% were males and (n=24) 30% were females. Tumor response was evaluated as CR in (n=45) 56% of patients, (n=26) 32% showed PR, (n=6) 8% had SD, while (n=3) 4% had PD. Most of the patients showed significant tumor necrosis, 70-90% tumor necrosis was seen in 52% of the patients. An association between gender (male participants; n=56) and tumor response to TACE (71 responded out of which 56 were males) was found to be significant. Conclusions: TACE is a better treatment option for unresectable and larger HCC if proper care, management, and continuation of disease assessment are done after the treatment, as it results in tumor burden reduction and improved chances of qualifying for liver transplant in suitable cases.

References

Mittal S, and El-Serag HB. Epidemiology of HCC: consider the population. Journal of Clinical Gastroenterology. 2013 Jul; 47: S2. doi: 10.1097/MCG.0b013e3182872f29. DOI: https://doi.org/10.1097/MCG.0b013e3182872f29

Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011 Apr; 140(4): 1182-8. doi: 10.1053/j.gastro.2010.12.032. DOI: https://doi.org/10.1053/j.gastro.2010.12.032

Majid A, and Khan MR. Determining the efficacy of trans-arterial chemoembolization for hepatocellular carcinoma on follow-up quadriphasic computed tomography. Pakistan Journal of Radiology. 2019 Oct; 29(3): 149-54.

Sun VC, and Sarna L. Symptom management in hepatocellular carcinoma. Clinical Journal of Oncology Nursing. 2008 Oct; 12(5): 759. doi: 10.1188/08.CJON.759-766. DOI: https://doi.org/10.1188/08.CJON.759-766

Lau WY, Simon CH, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. Journal of the American College of Surgeons. 2006 Jan; 202(1): 155-68. doi: 10.1016/j.jamcollsurg.2005.06.263. DOI: https://doi.org/10.1016/j.jamcollsurg.2005.06.263

Imai N, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, et al. Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques. World Journal of Hepatology. 2014 Dec; 6(12): 844. doi: 10.4254/wjh.v6.i12.844. DOI: https://doi.org/10.4254/wjh.v6.i12.844

Yang D, Woodard G, Zhou C, Wang X, Liu Z, Ye Z, et al. Significance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics. Thoracic Cancer. 2016 Sep; 7(5): 535-42. doi: 10.1111/1759-7714.12363. DOI: https://doi.org/10.1111/1759-7714.12363

Nishino M. Tumor response assessment for precision cancer therapy: response evaluation criteria in solid tumors and beyond. American Society of Clinical Oncology Educational Book. 2018 May; 38: 1019-29. doi: 10.1200/EDBK_201441. DOI: https://doi.org/10.1200/EDBK_201441

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours. European Journal of Cancer. 2009 Jan; 45(2): 228-47. doi: 10.1016/j.ejca.2008.10.026. DOI: https://doi.org/10.1016/j.ejca.2008.10.026

Fogel A, McCrickerd K, Aris IM, Goh AT, Chong YS, Tan KH, et al. Eating behaviors moderate the associations between risk factors in the first 1000 days and adiposity outcomes at 6 years of age. The American Journal of Clinical Nutrition. 2020 May; 111(5): 997-1006. doi: 10.1093/ajcn/nqaa052. DOI: https://doi.org/10.1093/ajcn/nqaa052

Murphy A, Dabirifar S, Bell D. CT triple-phase liver (protocol). Radiopedia. 29th Jul. doi: 10.53347/rID-94730. DOI: https://doi.org/10.53347/rID-94730

Kwan SW, Fidelman N, Ma E, Kerlan Jr RK, Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological‐pathological correlation. Liver Transplantation. 2012 Jun; 18(6): 727-36. doi: 10.1002/lt.23413. DOI: https://doi.org/10.1002/lt.23413

Dioguardi Burgio M, Sartoris R, Libotean C, Zappa M, Sibert A, Vilgrain V, et al. Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response. Cancer Imaging. 2019 Dec; 19: 1-9. doi: 10.1186/s40644-019-0260-2. DOI: https://doi.org/10.1186/s40644-019-0260-2

Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Advances in Therapy. 2008 Aug; 25: 787-94. doi: 10.1007/s12325-008-0079-x. DOI: https://doi.org/10.1007/s12325-008-0079-x

Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (< 5 cm) hepatocellular carcinomas. Hepatology. 2011 May; 53(5): 1580-9. doi: 10.1002/hep.24246. DOI: https://doi.org/10.1002/hep.24246

Prajapati HJ, Xing M, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, et al. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. American Journal of Roentgenology. 2014 Dec; 203(6): W706-14. doi: 10.2214/AJR.13.12308. DOI: https://doi.org/10.2214/AJR.13.12308

Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, et al. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World Journal of Gastroenterology: WJG. 2007 Jun; 13(21): 2952. doi: 10.3748/wjg.v13.i21.2952. DOI: https://doi.org/10.3748/wjg.v13.i21.2952

Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K, et al, Japan Interventional Radiology In Oncology Study Group (JIVROSG). Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Upsala Journal of Medical Sciences. 2013 Mar; 118(1): 16-22. doi: 10.3109/03009734.2012.729104. DOI: https://doi.org/10.3109/03009734.2012.729104

Roth G, Teyssier Y, Benhamou M, Abousalihac M, Caruso S, Sengel C, et al. Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization. World Journal of Gastroenterology. 2022 Sep; 28(36): 5324. doi: 10.3748/wjg.v28.i36.5324. DOI: https://doi.org/10.3748/wjg.v28.i36.5324

Cappelli A, Cucchetti A, Cabibbo G, Mosconi C, Maida M, Attardo S, et al. Refining prognosis after trans‐arterial chemo‐embolization for hepatocellular carcinoma. Liver International. 2016 May; 36(5): 729-36. doi: 10.1111/liv.13029. DOI: https://doi.org/10.1111/liv.13029